Green Bay, WI (June 1, 2006) -- French scientists have discovered a revolution in Omega-3 supplements, and EuroPharma is bringing it to the US market. EuroPharma has entered into an exclusive North American distribution agreement for Vectomega®, a natural marine complex made up of five different phospholipids, DHA and EPA, along with proteins and amino acids as they occur in nature.

Omega 3 fish oils have become increasingly popular in response to a growing body of science on its health benefits. Vectomega® uses a biological innovation that extracts naturally occurring marine phospholipids with the omega-3 fatty acids, EPA and DHA. Other fish oil products do not contain these marine phospholipids. This patented innovation, called vectorization, uses a gentle, cold water and enzyme process avoiding heat, solvents, and chemical modifications that are utilized to process all other fish oils.

Vectomega’s® phospholipid vectorization has been clinically demonstrated to have superior bioavailability compared to other fish oils. In technical terms, the amphiphilic properties of the marine phospholipids can easily cross the hydrophilic membrane barriers for superior bioabsorption compared to “neutrally charged” commercial fish oils on the market today. Research has confirmed that 50 times more Vectomega® DHA and EPA crosses the cell membrane as compared to standard commercial fish oil products.

At the therapeutic dose, 2 tablets (600 mg) of Vectomega® are equal to 16 capsules (7,200 mg) of standard fish oil. Research has shown that because the marine phospholipids contain DHA and EPA in a specific location on the carbon chain (Sn-2 on the glycerol), Vectomega® is 50 times more absorbable via cell membranes.

“There is vast scientific data supporting the benefits of fish oil and its impact on the quality of health, including cardiovascular, cognitive function, joint mobility, anti-inflammatory action, improved liver function, vision and auditory health, cholesterol lowering including LDL levels, and anti-depressant properties,” stated Terry Lemerond, president of EuroPharma. “Vectomega® surpasses other fish oil products in terms of bioavailability, absorption and efficacy. The addition of Vectomega® to any commercial application will dramatically re-position any food product into a health product, thus increasing its market potential.”

This new marine phospholipid omega-3 supplement is available in dry water soluble powder, ideal for many functional food applications (milk drinks, infant formulas, other beverages, soups, sauces, salad dressings, frozen prepared meals, pastas, spreads, yogurts, cheeses, egg substitutes and nutrition bars) and dietary supplement formulation applications (tablets, capsules).

For more information, availability and pricing, visit www.EuroPharmaUSA.com or contact Lisa Joski, [email protected], 920-406-6500.

Located in Green Bay, Wisconsin, EuroPharma, Inc., is committed to discovering innovative products that have been extensively researched and demonstrated to be safe, natural and effective which will help people live healthier and more fulfilling lives. EuroPharma’s mission is to bring truly unique and industry changing products to the U.S. marketplace. EuroPharma is an extension of its founder, Terry Lemerond’s historic successes and a proven model of product development.

- END -